Related references
Note: Only part of the references are listed.A whole-animal platform to advance a clinical kinase inhibitor into new disease space
Masahiro Sonoshita et al.
NATURE CHEMICAL BIOLOGY (2018)
CASTp 3.0: computed atlas of surface topography of proteins
Wei Tian et al.
NUCLEIC ACIDS RESEARCH (2018)
Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling
Xiaochao Zhang et al.
CELL DEATH & DISEASE (2018)
Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition
E. Leroy et al.
LEUKEMIA (2017)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Shubhasree Banerjee et al.
DRUGS (2017)
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
M. Buchert et al.
ONCOGENE (2016)
Identification of 8-Hydroxyquinoline Derivatives Active Against Somatic V658F Mutant JAK1-Dependent Cells
Robert Kiss et al.
ARCHIV DER PHARMAZIE (2016)
Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors
Vladimir Simov et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Cancer treatment and survivorship statistics, 2016
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity
Chao Zhao et al.
CURRENT MEDICINAL CHEMISTRY (2016)
FDA-approved small-molecule kinase inhibitors
Peng Wu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model
Sandrine Degryse et al.
BLOOD (2014)
S-Phase Cell Cycle Arrest, Apoptosis, and Molecular Mechanisms of Aplasia Ras homolog Member I-Induced Human Ovarian Cancer SKOV3 Cell Lines
Qiaoying Zhu et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2014)
Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)
T. Zhou et al.
LEUKEMIA (2014)
Considering the impact drug-like properties have on the chance of success
Iskander Yusof et al.
DRUG DISCOVERY TODAY (2013)
MECHANISMS OF DISEASE JAKs and STATs in Immunity, Immunodeficiency, and Cancer
John J. O'Shea et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
JAK/STAT signaling in hematological malignancies
W. Vainchenker et al.
ONCOGENE (2013)
STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain
Olga A. Timofeeva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review
Tiejun Cheng et al.
AAPS JOURNAL (2012)
Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery
Xuan-Yu Meng et al.
Current Computer-Aided Drug Design (2012)
Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
J. Mascarenhas et al.
CURRENT MEDICINAL CHEMISTRY (2012)
JAK2 inhibition for the treatment of hematologic and solid malignancies
Brian L. Harry et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway
Wan Du et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells
Hua Xiong et al.
MOLECULAR CARCINOGENESIS (2012)
Quantifying the chemical beauty of drugs
G. Richard Bickerton et al.
NATURE CHEMISTRY (2012)
Ruxolitinib
Ruben A. Mesa et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
JAK2 inhibitors: What's the true therapeutic potential?
Fabio P. S. Santos et al.
BLOOD REVIEWS (2011)
iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis
Kai-Cheng Hsu et al.
BMC BIOINFORMATICS (2011)
STAT3 Is Necessary for Proliferation and Survival in Colon Cancer-Initiating Cells
Li Lin et al.
CANCER RESEARCH (2011)
The Use of Structural Biology in Janus Kinase Targeted Drug Discovery
Nilda L. Alicea-Velazquez et al.
CURRENT DRUG TARGETS (2011)
Discovery of 1-Amino-5H-pyrido[4,3-b]indol-4-carboxamide Inhibitors of Janus Kinase 2 (JAK2) for the Treatment of Myeloproliferative Disorders
Jongwon Lim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
No evidence for JAK2 V617F mutation in colorectal cancer
M. Herreros-Villanueva et al.
BRITISH JOURNAL OF BIOMEDICAL SCIENCE (2010)
The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases
Yasumichi Hitoshi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
Jonathan B. Baell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2
Mark W. Ledeboer et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening
Robert Kiss et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Janus Kinase 2 Inhibitors. Synthesis and Characterization of a Novel Polycyclic Azaindole
Tiansheng Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Lestaurtinib: a multi-targeted FLT3 inhibitor
Amir T. Fathi et al.
EXPERT REVIEW OF HEMATOLOGY (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Absence of JH2 domain mutation of the tyrosine kinase JAK2 in renal cell carcinomas
Jianming Zhao et al.
ACTA ONCOLOGICA (2008)
A pharmacophore map of small molecule protein kinase inhibitors
Malcolm J. McGregor
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2007)
BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities
Tiqing Liu et al.
NUCLEIC ACIDS RESEARCH (2007)
Absence of JAK2 V617F mutation in gastric cancers
JW Lee et al.
ACTA ONCOLOGICA (2006)
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vanicha Vichai et al.
NATURE PROTOCOLS (2006)
A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells
J Turkson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A pharmacophore-based evolutionary approach for screening selective estrogen receptor modulators
JM Yang et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
The JAK/STAT signaling pathway
JS Rawlings et al.
JOURNAL OF CELL SCIENCE (2004)
Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations
C Bissantz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
